Edesa Biotech (EDSA)
(Delayed Data from NSDQ)
$4.47 USD
+0.16 (3.68%)
Updated Apr 25, 2024 03:31 PM ET
After-Market: $4.49 +0.02 (0.48%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Edesa Biotech, Inc falls in the month of September.
All items in Millions except EPS data.
9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 9 | 18 | 24 | 7 | 3 |
Income After Depreciation & Amortization | -9 | -18 | -24 | -6 | -3 |
Non-Operating Income | 1 | 1 | 10 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -8 | -18 | -13 | -6 | -3 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -8 | -18 | -13 | -6 | -3 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -8 | -18 | -13 | -6 | -3 |
Depreciation Footnote | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -9 | -18 | -24 | -6 | -3 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -9 | -18 | -24 | -6 | -3 |
Earnings Per Share Data | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Average Shares | 2.86 | 2.38 | 1.73 | 1.23 | NA |
Diluted EPS Before Non-Recurring Items | -2.93 | -7.35 | -7.70 | -5.18 | -26.52 |
Diluted Net EPS (GAAP) | -2.93 | -7.35 | -7.70 | -5.18 | -26.52 |
Fiscal Year end for Edesa Biotech, Inc falls in the month of September.
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.85 | 2.37 | 2.07 | 2.41 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -1.85 | -2.37 | -2.07 | -2.41 |
Non-Operating Income | NA | 0.18 | 0.65 | 0.08 | 0.08 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -1.68 | -1.72 | -1.98 | -2.33 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.68 | -1.72 | -1.98 | -2.33 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.68 | -1.72 | -1.98 | -2.33 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 3.13 | NA | 2.93 | 2.85 |
Diluted EPS Before Non-Recurring Items | NA | -0.54 | NA | -0.70 | -0.84 |
Diluted Net EPS (GAAP) | NA | -0.54 | -0.48 | -0.70 | -0.84 |